Searched for
GSK INDIA EARNINGS
Ahead of Market: 10 things that will decide stock market action on FridayIndian equities witnessed sharp swings before ending lower amid expiry-day volatility and rising geopolitical concerns. Profit booking in b...- Haleon Appoints Former Castrol MD Kedar Lele as India Subcontinent PresidentHaleon has appointed Kedar Lele as president, India subcontinent, succeeding Navneet Saluja. Lele, formerly managing director of Castrol In...
- GSK India Q2 Results: Net profit grows 11% YoY to Rs 216 croreOur Q2 performance reflects an overall recovery with market share gains in several key promoted brands across all business units. We held l...
- GSK Pharma tumbles 12% after posting Rs 660-crore Q3 lossThe company's consolidated revenue from operations stood at Rs 778.59 crore for the quarter under consideration.
- Lower royalty payout is likely to boost EPS of MNCs’ local unitsHUL is expected to pay 3.4 per cent of EBITDA as royalty in FY2019
- HUL’s earnings likely to rise 4% post GSK Consumer dealHUL has invested almost Rs 3,000 crore in the foods business over the last 10 years.
- Why Horlicks may not be such a sweet deal for UnileverUnilever’s purchase of GSK's unit, including Horlicks, comes as Indians lose their taste for sugary drinks.
- Royalty payment curbs a boost for MNC unitsRoyalty payment of Maruti in the third quarter of FY18 stood at 5.3 per cent of sales.
- GST to hit GSK Consumer's global growth, says CFO Simon DingemansUK healthcare company, the maker of Boost and Horlicks, also lists other factors for subdued show in 2018.
- Continued pressure on Horlicks, destocking negatively impacted nutrition business: GSK
- Pick-up in local market boosts pharma MNCsA pick-up in the local pharma market augurs well for MNCs which are still recovering from the adverse impact of drug price control on high-...
- Domestic pharma companies may gain as MNCs set to swallow bitter marketing pillA cautious strategy adopted by MNCs in promoting medicines could affect MNCs, including GSK, and impact their growth prospects in the India...
- $1 billion bet: GSK Pharma a short-term sell, long-term buy, say expertsThe stock is at rich valuations despite low sales and profit growth. The open offer by its parent firm is attractively priced, say experts.
- GSK Pharma rallies 20% as parent initiates open offerThe parent of GlaxoSmithKline Pharmaceuticals Ltd plans to increase its stake from 50.7 per cent to up to 75 per cent at an offer price of ...
- GSK Pharma: Price control may prove costly for companyMultinational drug maker GSK Pharma’s good show in 2012 masks a key concern for the company, the new drug pricing control order.
- GSK to raise stake in GlaxoSmithKline Consumer Healthcare via open offerGlaxoSmithKline plans to raise its stake in its Indian consumer products arm to 75 per cent from 43.16 per cent through an open offer.
- GSK Pharma: Investors must be careful of the competitive threats it faces in IndiaWhile the company's performance in the June quarter was strong sequentially, it will be interesting to see GSK's strategies to overcome the...
- GSK drug-deal talk lifts DRL scripShares of Dr Reddy’s Laboratories (DRL) touched an intra-day high of Rs 878.70, amid speculation that the Indian drug maker is in prelimina...
- More drug MNCs join the stake-hike bandwagonAfter the two leading pharma multinationals recently increased their stakes in their Indian units, people connected with the industry say t...
- Ranbaxy starts study on new respiratory inflammation medicineIndia's largest drugmaker Ranbaxy Laboratories has started initial clinical studies (Phase I) on the lead compound to develop a new respira...
Load More
